Dr. Vineeth Mohan, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
Medicare and federal program status
Opted out of Medicare from April 1, 2024 through April 1, 2028. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated April 16, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 46
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME95884
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 46
- Services billed
- 564
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 2,640 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 351 | 255 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 105 | 68 |
| Ultrasound scan of head and neck soft tissue | 101 | 95 |
| New patient office or other outpatient visit, 45-59 minutes | 82 | 82 |
| Injection of drug or substance under skin or into muscle | 56 | 36 |
| Established patient office or other outpatient visit, 40-54 minutes | 53 | 49 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 32 | 28 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 24 | 22 |
| Established patient office or other outpatient visit, 20-29 minutes | 22 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Boca Raton, FL | 179 |
| Jardiance (empagliflozin) Other prescribers in Boca Raton, FL | 79 |
| Synthroid (levothyroxine sodium) Other prescribers in Boca Raton, FL | 59 |
| Metformin Hcl Other prescribers in Boca Raton, FL | 50 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Boca Raton, FL | 50 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Boca Raton, FL | 42 |
| Mounjaro (tirzepatide) Other prescribers in Boca Raton, FL | 42 |
| Methimazole Other prescribers in Boca Raton, FL | 33 |
| Trulicity (dulaglutide) Other prescribers in Boca Raton, FL | 33 |
| Tradjenta (linagliptin) Other prescribers in Boca Raton, FL | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 19 payments worth $8,613 in total to this clinician.
| Ascendis Pharma Endocrinology Inc | $8,190 |
|---|---|
| Sequel Med Tech, LLC | $152 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $56.07 |
| Alkermes, Inc. | $47.48 |
| Amgen Inc. | $45.88 |
| Sanofi-aventis U.S. LLC | $43.16 |
| Corcept Therapeutics | $24.00 |
| Madrigal Pharmaceuticals | $20.42 |
| Compensation for services other than consulting (speaking, faculty) | $8,177 |
|---|---|
| Food and Beverage | $436 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Yorvipath · Endocrinology | $5,746 |
| Ascendis Pharma Endocrinology Inc Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) Yorvipath · Endocrinology | $1,326 |
| Ascendis Pharma Endocrinology Inc Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) Yorvipath · Endocrinology | $1,105 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,283 in research payments for these studies, mostly to the institutions running them.
- Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
Ascendis Pharma Endocrinology Inc · Approved for marketing · NCT05654701
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.